385
de Vries, T.A.C., Hemels, M.E.W., Cools, F., Crijns, H.J.G.M., Yperzeele, L., Vanacker, P., Blankoff, I., Lancellotti, P., Mairesse, G.H., de Veer, A., Arroyo, R.C., Catez, E., de Pauw, M., Vanassche, T., de Asmundis, C., Kirchhof, P., De Caterina, R., de Groot, J.R., ETNA-AF-Europe, P.r.i.n.c.i.p.a.l.
Veröffentlicht in: de Vries , T A C , Hemels , M E W , Cools , F , Crijns , H J G M , Yperzeele , L , Vanacker , P , Blankoff , I , Lancellotti , P , Mairesse , G H , de Veer , A , Arroyo , R C , Catez , E , de Pauw , M , Vanassche , T , de Asmundis , C , Kirchhof , P , De Caterina , R , de Groot , J R , ETNA-AF-Europe , P R I N C I P A L & ETNA-AF-Europe principal investigators from Belgium and the Netherlands 2021 , ' Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study ' , Netherlands Heart Journal , vol. 29 , no. 3 , pp. 158-167 . https://doi.org/10.1007/s12471-020-01518-7;
2021
Volltext

Suche einschränken